At the drug intervention level, potential clinical drug–target interactions were revealed for CBR1 and PRDX1 based on the DGIdb: CBR1 interacts with six drugs, including WEDOLOLACTONE and N6022, suggesting its involvement in anti-inflammatory and antioxidant regulation during COPD pathogenesis; similarly, PRDX1 was found to be associated with six drug molecules, including general antioxidants, further supporting its critical influence in oxidative stress response and immune modulation (Figure 5E). Here, CBR1 is linked to chronic obstructive pulmonary disease.